fda announcement tirzepatide Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity FDA Says Shortage of GLP-1

Breaking down the results: 63% of participants lost 10% or more of their body weight 30% of participants lost 20% or more of their body weight Weight loss was accompanied by improvements in blood pressure, blood sugar control, and cholesterol levels The results of oral Wegovy are comparable to those seen with the weekly Wegovy injection

That same 20 units at 10 mg/mL would only deliver 2 mg

Many patients experience profound appetite suppression, which can inadvertently lead to insufficient protein and micronutrient intake

It also requires more precise reconstitution calculations since you are drawing smaller volumes more frequently